Review of Anti-VEGF Therapy in Proliferative Diabetic Retinopathy

REFERENCES

• The Eye Diseases Prevalence and Research Group. Causes and prevalence of visual impairment among adults in the United States. Arch Ophthalmol 2004; 122(2)477–485
   Google Scholar
• Early Treatment Diabetic Retinopathy Study Research Group. Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS report number 12. Ophthalmology 1991; 98: 823–833
   PubMed Web of Science ®Google Scholar
• Vander J F, Duker J S, Benson W E, et al. Long term stability and visual outcome after favorable initial response of proliferative diabetic retinopathy to panretinal photocoagulation. Ophthalmology 1991; 98(10)1575–1579
   PubMed Web of Science ®Google Scholar
• Flynn H W, Jr., Chew E Y, Simons B D, et al. Pars plana vitrectomy in the Early Treatment Diabetic Retinopathy Study. ETDRS report number 17. Ophthalmology 1992; 99: 1351–1357
   PubMed Web of Science ®Google Scholar
• Aiello L P. Angiogenic pathways in diabetic retinopathy. N Engl J Med 2005; 353(8)839–841
   PubMed Web of Science ®Google Scholar
• Early Treatment Diabetic Retinopathy Study Research Group. Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Ophthalmology 1991; 98: 766–785
   PubMed Web of Science ®Google Scholar
• Aiello L P, Avery R L, Arrigg P G, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994; 331(22)1480–1487
   PubMed Web of Science ®Google Scholar
• Ng E W, Adamis A P. Anti-VEGF aptamer (pegaptanib) therapy for ocular vascular diseases. Ann N Y Acad Sci 2006; 1082: 151–171
   PubMed Web of Science ®Google Scholar
• Saint-Geniez M, Maharaj A SR, Walshe T E, et al. Endogenous VEGF is required for visual function: Evidence for a survival role on Muller cells and photoreceptors. PLoS ONE 2008; 3(11)e3554, Epub 2008 Nov 3
   PubMed Web of Science ®Google Scholar
• Ishida S, Usui T, Yamashiro K, et al. VEGF164-mediated inflammation is required for pathological, but not physiological, ischemia-induced retinal neovascularization. J Exp Med 2003; 198(3)483–489
   PubMed Web of Science ®Google Scholar
• Patz A. Studies on retinal neovascularization. Invest Ophthalmol Vis Sci 1980; 19: 1133–1138
   PubMed Web of Science ®Google Scholar
• Aiello L P. Clinical implications of vascular growth factors in proliferative retinopathies. Curr Opin Ophthalmol 1997; 8(3)19–31
   Google Scholar
• Hussain N, Ghanekar Y, Kaur I. The future implications and indications of anti-vascular endothelial growth factor therapy in ophthalmic practice. Indian J Ophthalmol 2007; 55(6)445–450
   Google Scholar
• Watanabe D, Suzuma K, Suzuma I, Ohashi H, Ojima T, Kurimoto M, Murakami T, Kimura T, Takagi H. Vitreous levels of angiopoietin 2 and vascular endothelial growth factor in patients with proliferative diabetic retinopathy. Am J Ophthalmol 2005; 139(3)476–481
   PubMed Web of Science ®Google Scholar
• Watanabe D, Suzuma K, Matsui S, et al. Erythropoietin as a retinal angiogenic factor in proliferative diabetic retinopathy. N Engl J Med 2005; 353: 782–792
   PubMed Web of Science ®Google Scholar
• Tolentino M J, McLeod D S, Taomoto M, et al. Pathologic features of vascular endothelial growth factor-induced retinopathy in the nonhuman primate. Am J Ophthalmol 2002; 133: 373–385
   PubMed Web of Science ®Google Scholar
• Tolentino M J, Miller J W, Gragoudas E S, et al. Intravitreous injections of vascular endothelial growth factor produce retinal ischemia and microangiopathy in an adult primate. Ophthalmology 1996; 103: 1820–1828
   PubMed Web of Science ®Google Scholar
• Qaum T, Xu Q, Joussen A M, Clemens M W, Qin W, Miyamoto K, Hassessian H, Wiegand S J, Rudge J, Yancopoulos G D, Adamis A P. VEGF-initiated blood-retinal barrier breakdown in early diabetes. Invest Ophthalmol Vis Sci 2001; 42(10)2408–2413
   PubMed Web of Science ®Google Scholar
• Aiello L P, Pierce E A, Foley E D, et al. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc Natl Acad Sci USA 1995; 92: 10457–10461
   PubMed Web of Science ®Google Scholar
• Adamis A P, Shima D T, Tolentino M J, et al. Inhibition of vascular endothelial growth factor prevents retinal ischemia associated iris neovascularization in a nonhuman primate. Arch Ophthalmol 1996; 114: 66–71
   PubMed Web of Science ®Google Scholar
• https://www.clinicaltrials.gov
   Google Scholar
• Eugene W M, Shima D T, Calias P, et al. Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat Rev 2006; 5: 123–132
   Google Scholar
• Gragoudas E S, Adamis A P, Cunningham E T, Jr. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004; 351(27)2805–2816
   PubMed Web of Science ®Google Scholar
• Ng E W, Adamis A P. Targeting angiogenesis, the underlying disorder in neovascular age-related macular degeneration. Can J Ophthalmol 2005; 40: 352–368
   PubMed Web of Science ®Google Scholar
• VEGF Inhibition Study in Ocular Neovascularization (V. I. S. I. O. N.) Clinical Trial Group, Chakravarthy U, Adamis A P, Cunningham E T, Jr, Goldbaum M, Guyer D R, Katz B, Patel M. Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration. Ophthalmology Sep, 2006; 113(9)1508.e1–25
   Google Scholar
• Mendrinos E, Donati G, Pournaras C J. Rapid and persistent regression of severe new vessels on the disc in proliferative diabetic retinopathy after a single intravitreal injection of pegaptanib. Acta Ophthalmol Nov 18, 2008, (in press)
   Google Scholar
• Macugen Diabetic Retinopathy Study Group. A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology 2005; 112: 1747–1757
   PubMedGoogle Scholar
• Simo R, Hernadez C. Intravitreous anti-VEGF for diabetic retinopathy: Hopes and fears for a new therapeutic strategy. Diabetologia 2008; 51(9)1574–1580
   PubMed Web of Science ®Google Scholar
• Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335–2342
   PubMed Web of Science ®Google Scholar
• Rosenfeld P F, Moshfegi A A, Puliafito C A. Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 2005; 36(4)331–335
   PubMed Web of Science ®Google Scholar
• Rosenfeld P J, Fung A E, Puliafito C A. Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for macular edema from central retinal vein occlusion. Ophthalmic Surg Lasers Imaging 2005; 36(4)336–339
   PubMedGoogle Scholar
• Schwartz S G, Hickey M, Puliafito C A. Bilateral CRAO and CRVO from thrombotic thrombocytopenic purpura: OCT findings and treatment with triamcinolone acetonide and bevacizumab. Opthlamic Surg Lasers Imaging 2006; 37(5)420–422
   Google Scholar
• Avery R L. Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment. Retina 2006; 26(3)352–354
   PubMedGoogle Scholar
• Mason J O, III, Albert M A, Jr., Vail R. Intravitreal bevacizumab (Avastin) for refractory pseudophakic cystoid macular edema. Retina 2006; 26(3)356–357
   Google Scholar
• Avery R L, Pearlman J, Pieramici D J, et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology 2006; 113(10)1695–1705; e1–15
   PubMedGoogle Scholar
• Sawada O, Kawamura H, Kakinoki M, Ohji M. Vascular endothelial growth factor in fellow eyes of eyes injected with intravitreal bevacizumab. Grafes Arch Clin Exp Ophthalmol 2008; 246: 1379–1381
   PubMed Web of Science ®Google Scholar
• Jorge R, Costa R A, Calucci D, et al. Intravitreal bevacizumab (Avastin) for persistent new vessels in diabetic retinopathy (IBEPE study). Retina 2006; 26(9)1006–1013
   PubMed Web of Science ®Google Scholar
• Spaide R F, Fisher Y L. Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage. Retina 2006; 26(3)275–278
   PubMed Web of Science ®Google Scholar
• Jiang Y, Liang X, Li X, Tao Y, Wang K. Analysis of the clinical efficacy of intravitreal bevacizumab in the treatment of iris neovascularization caused by proliferative diabetic retinopathy. Acta Ophthalmol Sep 18, 2008, (in press)
   Google Scholar
• Mordenti J, Cuthbertson R A, Ferrara N, et al. Comparisons of the intraocular tissue distribution, pharmacokinetics, and safety of 125I-labeled full-length and Fab antibodies in rhesus monkeys after intravitreal administration. Toxicol Pathol 1999; 27: 536–544
   PubMed Web of Science ®Google Scholar
• Deissler H, Deissler H, Lang S, Lang G E. VEGF-induced effects on proliferation, migration and tight junctions are restored by ranibizumab (Lucentis) in microvascular retinal endothelial cells. Br J Ophthalmol 2008; 92: 839–843
   PubMed Web of Science ®Google Scholar
• Chun D W, Heier J S, Topping T M, et al. A pilot study of multiple intravitreal injections of ranibizumab in patients with center-involving clinically significant diabetic macular edema. Ophthalmology 2006; 113(10)1706–1712
   PubMed Web of Science ®Google Scholar
• Nguyen Q D, Tatlipinar S, Shah S M, et al. Vascular endothelial growth factor is a critical stimulus for diabetic macular edema. Am J Ophthalmol 2006; 142(6)961–969
   PubMed Web of Science ®Google Scholar
• Schwartz S G, Flynn H W, Jr. Pharmacotherapies for diabetic retinopathy: Present and future. Exp Diabetes Res 2007, ID 52487
   PubMedGoogle Scholar
• Brown D M, Kaiser P K, Michels M, et al. Ranibizumab versus verteporfin for neovascular age related macular degeneration. N Engl J Med 2006; 355(14)1432–1444
   PubMed Web of Science ®Google Scholar
• Heier J S, Antoszyk A N, Pavan P R, et al. Ranibizumab for the treatment of neovascular age related macular degeneration. A PhaseI/II multicenter, controlled multidose study. Ophthalmology 2006; 113(4)633–642
   PubMed Web of Science ®Google Scholar
• Rosenfeld P J, Brown D M, Heier J S, et al. Ranibizumab for neovascular age related macular degeneration. N Engl J Med 2006; 335(14)1491–1531
   Google Scholar
• Pieramici D J, Avery R L, Castellarin A A, et al. Case of anterior uveitis after intravitreal injection of bevacizumab. Retina 2006; 26(7)841–842
   Google Scholar
• Lee C S, Koh H J. Multiple retinal haemorrhages in diabetic retinopathy after adjunctive intravitreal bevacizumab (Avastin) with pars plana vitrectomy. Acta Ophthalmol Dec 18, 2007, (in press)
   Google Scholar
• Krzystolik M G, Filippopoulos T, Ducharme J F, Loewenstein J I. Pegaptanib as an adjunctive treatment for complicated neovascular diabetic retinopathy. Arch Ophthalmol 2006; 124(6)920–921
   Google Scholar
• Chen E, Park C H. Use of intravitreal bevacizumab as preoperative adjunct for tractional retinal detachment repair in severe proliferative diabetic retinopathy. Retina 2006; 26(6)699–700
   PubMedGoogle Scholar
• Rizzo S, Genovesi-Ebert F, Di Bartolo E, et al. Injection of intravitreal bevacizumab (Avastin) as a preoperative adjunct before vitrectomy surgery in the treatment of severe proliferative diabetic retinopathy (PDR). Graefes Arch Clin Exp Ophthalmol 2008; 246(6)837–842
   Google Scholar
• Ishikawa K, Honda S, Tsukahara Y, Negi A. Preferable use of intravitreal bevacizumab as a pretreatment of vitrectomy for severe proliferative diabetic retinopathy. Eye Sep 21, 2007, (in press)
   Google Scholar
• Yang C M, Yeh P T, Yang C H, Chen M S. Bevacizumab pretreatment and long-acting gas infusion on vitreous clear-up after diabetic vitrectomy. Am J Ophthalmol 2008; 146: 211–217
   PubMed Web of Science ®Google Scholar
• Tonello M, Costa R A, Almeida F PP, et al. Panretinal photocoagulation versus PRP plus intravitreal bevacizumab for high risk proliferative diabetic retinopathy (IBeHi study). Acta Ophthalmol 2008; 86(4)385–389
   PubMed Web of Science ®Google Scholar
• Mishahi A, Roohiport R, Lashay A, et al. Bevacizumab-augmented retinal laser photocoagulation in proliferative diabetic retinopathy: A randomized double-masked clinical trial. Eur J Ophthalmol 2008; 18(2)263–269
   Google Scholar
• Mason J O, Yunker J J, Vail R, McGwin G, Jr. Intravitreal bevacizumab (Avastin) prevention of panretinal photocoagulation-induced complications in patients with severe proliferative diabetic retinopathy. Retina 2008; 28: 1319–1324
   PubMedGoogle Scholar
• Mason J O, III, Nixon P A, White M F. Intravitreal injection of bevacizumab (Avastin) as adjunctive treatment of proliferative diabetic retinopathy. Am J Ophthalmol 2006; 142(4)685–688
   PubMedGoogle Scholar
• Cheema R A, Al-Mubarak M M, Amin Y M, Cheema M A. Role of combined cataract surgery and intravitreal bevacizumab injection in preventing progression of diabetic retinopathy. J Cataract Refract Surg 2009; 35: 18–25
   PubMed Web of Science ®Google Scholar
• Wu L, Martínez-Castellanos M A, Quiroz-Mercado H, Arevalo J F, Berrocal M H, Farah M E, Maia M, Roca J A, Rodriguez F J, for the Pan American Collaborative Retina Group (PACORES). Twelve-month safety of intravitreal injections of bevacizumab (Avastin(R)): Results of the Pan-American Collaborative Retina Study Group (PACORES). Graefes Arch Clin Exp Ophthalmol Jan, 2008; 246(1)81–87
   PubMed Web of Science ®Google Scholar
• Shima C, Sakaguchi H, Gomi F, Kamei M, Ikuno Y, Oshima Y, Sawa M, Tsujikawa M, Kusaka S, Tano Y. Complications in patients after intravitreal injection of bevacizumab. Acta Ophthalmol Jun, 2008; 86(4)372–376
   Google Scholar
• Soliman W, Vinten M, Sander B, Soliman K A, Yehya S, Rahman M S, Larsen M. Optical coherence tomography and vessel diameter changes after intravitreal bevacizumab in diabetic macular oedema. Acta Ophthalmol Jun, 2008; 86(4)365–371
   Google Scholar
• Nishijima K, Ng Y S, Zhong L, Bradley J, Schubert W, Jo N, Akita J, Samuelsson S J, Robinson G S, Adamis A P, Shima D T. Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury. Am J Pathol Jul, 2007; 171(1)53–67
   PubMed Web of Science ®Google Scholar
• Saint-Geniez M, Maharaj A S, Walshe T E, Tucker B A, Sekiyama E, Kurihara T, Darland D C, Young M J, D'Amore P A. Endogenous VEGF is required for visual function: Evidence for a survival role on Müller cells and photoreceptors. PLoS ONE 2008; 3(11)e3554, Epub 2008 Nov 3
   PubMed Web of Science ®Google Scholar
• D'Amore P A. Vascular endothelial cell growth factor-A: Not just for endothelial cells anymore. Am J Pathol Jul, 2007; 171(1)14–18
   Google Scholar
• Maharaj A S, D'Amore P A. Roles for VEGF in the adult. Microvasc Res Sep-Nov, 2007; 74(2–3)100–113, (in press)
   PubMedGoogle Scholar